Hospital
The Queens Medical Center
The Queens Medical Center was paid $200.03M by Medicaid between Jan 2018 and Dec 2024, across 561 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoTHE QUEENS MEDICAL CENTER
HONOLULU, HI 96813
HONOLULU, HI 96813
33aNPI1184612764assigned 10/07/2005
33bProvider typePsychiatric Hospital Unit
28Total paid$200.03M
24GClaims2,466,453
24DCodes billed561
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 414,869 | $30.68M | |
| 2019 | 388,839 | $31.16M | |
| 2020 | 262,122 | $22.13M | |
| 2021 | 343,604 | $26.09M | |
| 2022 | 359,801 | $26.63M | |
| 2023 | 366,139 | $26.71M | |
| 2024incomplete | 331,079 | $36.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 68,759 | 60,436 | $37.43M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 40,579 | 35,308 | $35.81M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 56,951 | 50,371 | $35.36M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.0% | 14,856 | 14,065 | $12.09M |
| G0378 | Hospital observation service, per hour | 3.6% | 18,999 | 13,371 | $7.18M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 14,897 | 13,662 | $5.13M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 6,147 | 5,847 | $4.29M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.1% | 2,894 | 2,671 | $4.16M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.6% | 2,258 | 2,185 | $3.25M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.4% | 26,929 | 10,678 | $2.75M |
| J9271 | Injection, pembrolizumab, 1 mg | 1.3% | 434 | 298 | $2.52M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 49,303 | 40,778 | $2.46M |
549 more codes
| 11045 | 1.2% | 6,091 | $2.37M | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 9,955 | $2.26M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 6,424 | $2.13M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 3,473 | $1.87M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 2,311 | $1.79M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,209 | $1.38M |
| 70498 | <1% | 1,458 | $1.08M | |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 8,766 | $1.08M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,384 | $1.07M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,319 | $1.06M |
| 77386 | <1% | 2,074 | $906K | |
| 74183 | <1% | 1,541 | $880K | |
| 99218 | <1% | 10,290 | $853K | |
| 74174 | <1% | 635 | $819K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,854 | $797K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 279 | $694K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 10,685 | $649K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 22,541 | $631K |
| 95811 | <1% | 875 | $630K | |
| 71250 | <1% | 4,414 | $573K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 15,173 | $568K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 5,703 | $543K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 13,534 | $532K |
| 76642 | <1% | 4,131 | $522K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,479 | $467K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 18,688 | $458K |
| 36902 | <1% | 384 | $421K | |
| 62321 | <1% | 1,212 | $409K | |
| 90870 | <1% | 1,677 | $397K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14,979 | $394K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 20,621 | $389K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,226 | $378K |
| 99221 | <1% | 4,068 | $372K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 394 | $372K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 6,179 | $361K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 5,345 | $353K |
| 97161 | <1% | 6,503 | $351K | |
| 49450 | <1% | 964 | $322K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 61,568 | $319K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,814 | $317K |
| 0002A | <1% | 7,930 | $309K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13,169 | $307K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,348 | $304K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17,294 | $304K |
| 49083 | <1% | 719 | $298K | |
| 97597 | <1% | 4,316 | $296K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 987 | $292K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 42,607 | $289K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 6,670 | $287K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 6,628 | $287K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 8,617 | $286K |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 2,473 | $286K |
| 0001A | <1% | 7,732 | $283K | |
| 62323 | <1% | 1,515 | $267K | |
| 29581 | <1% | 4,403 | $264K | |
| 76536 | <1% | 2,602 | $257K | |
| 76770 | <1% | 3,017 | $255K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,022 | $240K |
| 36430 | <1% | 2,774 | $235K | |
| 94060 | <1% | 1,920 | $231K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 16,295 | $229K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,137 | $226K |
| 70496 | <1% | 1,652 | $213K | |
| 80061 | Lipid panel | <1% | 7,796 | $209K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,826 | $207K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 1,630 | $203K |
| 70491 | <1% | 1,460 | $193K | |
| 74175 | <1% | 809 | $191K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 4,086 | $172K |
| 72141 | <1% | 780 | $166K | |
| 72131 | <1% | 1,567 | $164K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,654 | $159K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 6,848 | $158K |
| 64483 | <1% | 421 | $158K | |
| 96415 | <1% | 2,210 | $152K | |
| 77301 | <1% | 40 | $148K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,455 | $142K |
| 75574 | <1% | 327 | $138K | |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | <1% | 76 | $138K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 29,015 | $131K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 7,275 | $125K |
| 93975 | <1% | 1,000 | $122K | |
| 93458 | <1% | 90 | $120K | |
| 77080 | <1% | 2,013 | $118K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 16,844 | $118K |
| 77334 | <1% | 174 | $117K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,315 | $115K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,312 | $114K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 213 | $113K |
| 93017 | <1% | 3,700 | $112K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,593 | $111K |
| 19083 | <1% | 141 | $110K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,243 | $110K |
| 86803 | <1% | 1,525 | $109K | |
| 87186 | <1% | 14,557 | $108K | |
| 20610 | <1% | 677 | $108K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 10,708 | $108K |
| 74178 | <1% | 126 | $107K | |
| 93246 | <1% | 1,750 | $102K | |
| 73562 | <1% | 5,144 | $100K | |
| 31575 | <1% | 669 | $99K | |
| 73110 | <1% | 3,119 | $89K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 130 | $88K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,300 | $88K |
| 0012A | <1% | 2,643 | $87K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 375 | $85K |
| 70486 | <1% | 2,977 | $85K | |
| 90837 | Psychotherapy session, about an hour | <1% | 985 | $83K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 1,056 | $78K |
| 73610 | <1% | 4,095 | $77K | |
| 73502 | <1% | 2,659 | $74K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 2,317 | $73K |
| 73030 | <1% | 5,032 | $72K | |
| 73630 | <1% | 5,708 | $71K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,774 | $71K |
| 11043 | <1% | 274 | $71K | |
| 72110 | <1% | 1,171 | $69K | |
| 77065 | Tomosynthesis, mammo | <1% | 3,052 | $68K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,934 | $68K |
| 0004A | <1% | 1,973 | $67K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,767 | $64K |
| 94726 | <1% | 831 | $62K | |
| 91322 | <1% | 408 | $61K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,556 | $61K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 87,952 | $60K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 17,524 | $60K |
| 97162 | <1% | 759 | $60K | |
| 80053 | Comprehensive metabolic panel | <1% | 34,963 | $57K |
| 93925 | <1% | 271 | $55K | |
| 93971 | <1% | 1,757 | $55K | |
| 73130 | <1% | 4,338 | $55K | |
| 0011A | <1% | 2,147 | $54K | |
| 72100 | <1% | 2,722 | $51K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,436 | $49K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 450 | $49K |
| 93923 | <1% | 964 | $48K | |
| 74018 | <1% | 2,205 | $48K | |
| 88341 | <1% | 1,900 | $48K | |
| 73700 | <1% | 286 | $47K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,028 | $46K |
| 10005 | <1% | 105 | $46K | |
| 0054A | <1% | 1,266 | $44K | |
| 91200 | <1% | 643 | $43K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 221 | $43K |
| 87340 | <1% | 1,614 | $43K | |
| 0071A | <1% | 1,057 | $42K | |
| 71271 | <1% | 380 | $42K | |
| 0072A | <1% | 976 | $41K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,280 | $37K |
| 93970 | <1% | 587 | $35K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,884 | $34K |
| 0064A | <1% | 1,105 | $33K | |
| 97165 | <1% | 1,534 | $32K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 404 | $32K |
| 86923 | <1% | 3,265 | $32K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 49 | $30K |
| 72197 | <1% | 37 | $30K | |
| 49505 | <1% | 16 | $28K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 13 | $27K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 211 | $27K |
| 83880 | <1% | 14,036 | $26K | |
| 72040 | <1% | 719 | $26K | |
| 95800 | <1% | 196 | $25K | |
| 94010 | <1% | 266 | $23K | |
| 71045 | Radiologic examination, chest; single view | <1% | 32,148 | $22K |
| 0296T | <1% | 763 | $22K | |
| 70544 | <1% | 68 | $21K | |
| 75561 | <1% | 24 | $21K | |
| 73080 | <1% | 2,003 | $21K | |
| 87075 | <1% | 8,514 | $19K | |
| 73552 | <1% | 1,120 | $18K | |
| 10140 | <1% | 28 | $18K | |
| 92610 | <1% | 331 | $18K | |
| 96416 | <1% | 110 | $18K | |
| 88342 | <1% | 2,566 | $18K | |
| 73560 | <1% | 2,360 | $17K | |
| 10060 | <1% | 1,029 | $17K | |
| 11044 | <1% | 44 | $16K | |
| 77412 | <1% | 408 | $16K | |
| 78306 | <1% | 237 | $15K | |
| 73221 | <1% | 38 | $15K | |
| 31505 | <1% | 108 | $15K | |
| 92557 | <1% | 208 | $15K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 1,398 | $14K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 82 | $14K |
| 85610 | <1% | 23,305 | $14K | |
| 92526 | <1% | 546 | $14K | |
| 73590 | <1% | 2,741 | $14K | |
| 36561 | <1% | 19 | $13K | |
| 36821 | <1% | 17 | $13K | |
| 82607 | <1% | 942 | $13K | |
| 10160 | <1% | 46 | $13K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 40 | $13K |
| 86850 | <1% | 9,882 | $12K | |
| 76882 | <1% | 301 | $12K | |
| 76641 | <1% | 112 | $12K | |
| 93350 | <1% | 38 | $11K | |
| 87480 | <1% | 819 | $11K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 17,543 | $11K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 32 | $11K |
| 73564 | <1% | 193 | $11K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 105,115 | $11K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,668 | $11K |
| 76813 | <1% | 79 | $10K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 435 | $10K |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 169 | $10K |
| 76801 | <1% | 315 | $10K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 14 | $10K |
| 99152 | <1% | 804 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,145 | $9K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 68 | $9K |
| G0008 | Administration of influenza virus vaccine | <1% | 194 | $9K |
| 0124A | <1% | 700 | $9K | |
| 82728 | <1% | 879 | $8K | |
| 0031A | <1% | 271 | $8K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 330 | $8K |
| 99205 | Prolong outpt/office vis | <1% | 27 | $8K |
| 31579 | <1% | 19 | $8K | |
| 82962 | <1% | 42,501 | $8K | |
| 76870 | <1% | 424 | $8K | |
| 73140 | <1% | 1,167 | $8K | |
| 88142 | <1% | 478 | $8K | |
| 10061 | <1% | 107 | $7K | |
| 76942 | <1% | 357 | $7K | |
| 92550 | <1% | 71 | $7K | |
| 96160 | <1% | 42,338 | $7K | |
| 82803 | <1% | 15,669 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 112 | $6K |
| 0052A | <1% | 132 | $6K | |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | <1% | 74 | $6K |
| 83970 | <1% | 82 | $5K | |
| 11404 | <1% | 18 | $5K | |
| 94729 | <1% | 1,786 | $5K | |
| 93312 | <1% | 24 | $5K | |
| 72050 | <1% | 92 | $5K | |
| 80076 | <1% | 27,194 | $5K | |
| 43235 | <1% | 14 | $5K | |
| 71101 | <1% | 920 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,918 | $5K |
| 82378 | <1% | 201 | $5K | |
| 84702 | <1% | 2,033 | $4K | |
| 96523 | <1% | 585 | $4K | |
| 73090 | <1% | 1,798 | $4K | |
| 11721 | <1% | 134 | $4K | |
| 96367 | <1% | 4,709 | $4K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,169 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,991 | $4K |
| 82043 | <1% | 2,114 | $4K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 1,626 | $4K |
| 74019 | <1% | 501 | $4K | |
| 87076 | <1% | 2,970 | $4K | |
| 99201 | <1% | 124 | $4K | |
| 0154A | <1% | 97 | $3K | |
| 0051A | <1% | 74 | $3K | |
| 73522 | <1% | 28 | $3K | |
| 88361 | <1% | 19 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,555 | $3K |
| 74230 | <1% | 30 | $3K | |
| 85027 | <1% | 10,660 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 34,683 | $3K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 20 | $3K |
| 88304 | <1% | 2,802 | $3K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 21 | $2K |
| 0074A | <1% | 56 | $2K | |
| 90651 | <1% | 32 | $2K | |
| 88143 | <1% | 15 | $2K | |
| 87077 | <1% | 12,417 | $2K | |
| 84484 | <1% | 41,706 | $2K | |
| 73060 | <1% | 686 | $2K | |
| 85379 | <1% | 5,359 | $2K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 53 | $2K |
| A4648 | Tissue marker, implantable, any type, each | <1% | 722 | $2K |
| 12001 | <1% | 1,101 | $2K | |
| 80069 | <1% | 967 | $2K | |
| 82947 | <1% | 5,574 | $2K | |
| 96411 | <1% | 182 | $2K | |
| 81001 | <1% | 33,353 | $2K | |
| 84145 | <1% | 5,996 | $2K | |
| 73000 | <1% | 83 | $2K | |
| 81025 | <1% | 14,988 | $2K | |
| 72170 | <1% | 1,719 | $2K | |
| 70487 | <1% | 13 | $2K | |
| 72072 | <1% | 40 | $2K | |
| 72128 | <1% | 339 | $2K | |
| 12002 | <1% | 850 | $2K | |
| 84134 | <1% | 3,871 | $1K | |
| 96401 | <1% | 40 | $1K | |
| 87070 | <1% | 11,358 | $1K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 49 | $1K |
| 0003A | <1% | 40 | $1K | |
| 90715 | <1% | 4,495 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 71 | $1K |
| 86704 | <1% | 653 | $1K | |
| 73660 | <1% | 319 | $1K | |
| 96040 | <1% | 26 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 15 | $1K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 552 | $1K |
| 93922 | <1% | 445 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 328 | $1K |
| 90480 | <1% | 544 | $1K | |
| 88333 | <1% | 322 | $1K | |
| 83605 | <1% | 18,767 | $1K | |
| 85730 | <1% | 15,876 | $1K | |
| 29125 | <1% | 325 | $1K | |
| 73120 | <1% | 41 | $1K | |
| 87040 | <1% | 13,421 | $1K | |
| 87510 | <1% | 806 | $1K | |
| J3490 | Unclassified drugs | <1% | 4,633 | $1K |
| 83690 | <1% | 24,359 | $1K | |
| 93296 | <1% | 62 | $979.33 | |
| 86900 | <1% | 10,162 | $837.18 | |
| 87660 | <1% | 807 | $832.84 | |
| 90836 | <1% | 187 | $757.41 | |
| 36591 | <1% | 91 | $750.00 | |
| 82330 | <1% | 8,001 | $746.18 | |
| 88172 | <1% | 919 | $712.75 | |
| 82270 | <1% | 123 | $702.62 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 31,191 | $623.80 |
| 0134A | <1% | 24 | $589.16 | |
| 96376 | <1% | 5,370 | $545.88 | |
| 81002 | <1% | 11,763 | $527.13 | |
| 82746 | <1% | 453 | $517.09 | |
| 80320 | <1% | 2,283 | $509.77 | |
| 77336 | <1% | 2,359 | $493.08 | |
| 93225 | <1% | 15 | $481.52 | |
| C1769 | Guide wire | <1% | 4,320 | $470.92 |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 13 | $441.33 |
| 83550 | <1% | 671 | $434.42 | |
| 86706 | <1% | 891 | $432.92 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,259 | $427.20 |
| 86140 | <1% | 8,915 | $420.54 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,321 | $416.16 |
| 93880 | <1% | 12 | $389.85 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 384 | $387.39 |
| 96161 | <1% | 3,398 | $381.71 | |
| 82570 | <1% | 2,731 | $379.20 | |
| 84132 | <1% | 10,655 | $372.84 | |
| 84550 | <1% | 1,750 | $342.16 | |
| 85670 | <1% | 2,302 | $337.47 | |
| 74022 | <1% | 25 | $336.99 | |
| 85014 | <1% | 15,129 | $335.03 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,269 | $325.76 |
| 83735 | <1% | 9,432 | $313.66 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,947 | $286.03 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,734 | $280.69 |
| 82550 | <1% | 3,287 | $264.37 | |
| 93280 | <1% | 27 | $264.10 | |
| 77012 | <1% | 13 | $253.69 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,864 | $246.05 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 6,834 | $240.91 |
| 82565 | <1% | 11,440 | $238.98 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 3,730 | $231.02 |
| 88307 | <1% | 1,809 | $229.11 | |
| 12011 | <1% | 337 | $225.10 | |
| 97116 | <1% | 480 | $223.54 | |
| 93976 | <1% | 143 | $221.93 | |
| 86359 | <1% | 12 | $213.93 | |
| 88312 | <1% | 896 | $208.50 | |
| 84703 | <1% | 2,712 | $203.40 | |
| 87210 | <1% | 963 | $195.67 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 2,866 | $189.24 |
| 73620 | <1% | 35 | $185.21 | |
| 86901 | <1% | 10,181 | $184.97 | |
| 84295 | <1% | 7,596 | $180.67 | |
| A9270 | Non-covered item or service | <1% | 47,951 | $166.50 |
| 85652 | <1% | 7,934 | $165.69 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 34,216 | $164.34 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,278 | $164.14 |
| 87088 | <1% | 6,518 | $159.63 | |
| 86735 | <1% | 29 | $156.61 | |
| 90785 | <1% | 17 | $156.00 | |
| 86592 | <1% | 1,511 | $154.95 | |
| 82140 | <1% | 239 | $146.69 | |
| 76376 | <1% | 1,131 | $146.49 | |
| 77300 | <1% | 376 | $145.33 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,873 | $127.95 |
| 87807 | <1% | 829 | $116.53 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16,594 | $116.42 |
| 84100 | <1% | 2,752 | $109.08 | |
| 86920 | <1% | 86 | $106.17 | |
| 94727 | <1% | 1,373 | $94.13 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,229 | $92.24 |
| Q3014 | Telehealth originating site facility fee | <1% | 17 | $83.16 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 191 | $81.93 |
| L4386 | Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 73 | $73.82 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 3,295 | $73.80 |
| 87205 | <1% | 11,240 | $71.71 | |
| 87116 | <1% | 17 | $69.62 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 36,025 | $69.03 |
| J2704 | Injection, propofol, 10 mg | <1% | 22,878 | $69.02 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,429 | $63.85 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,030 | $63.05 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 510 | $60.94 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,135 | $58.12 |
| 84439 | <1% | 1,842 | $47.61 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 4,860 | $42.48 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,035 | $42.25 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 428 | $42.15 |
| 82010 | <1% | 1,745 | $40.19 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 916 | $37.48 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 13,076 | $36.58 |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 84 | $34.72 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 5,140 | $30.55 |
| A9561 | Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries | <1% | 333 | $30.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,732 | $29.95 |
| C1729 | Catheter, drainage | <1% | 2,520 | $26.02 |
| 90686 | <1% | 1,367 | $25.98 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 568 | $25.00 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 558 | $24.15 |
| 92524 | <1% | 20 | $23.57 | |
| 96368 | <1% | 1,744 | $22.78 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,978 | $21.08 |
| 94761 | <1% | 94 | $20.50 | |
| 92567 | <1% | 197 | $20.45 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 177 | $20.16 |
| 87147 | <1% | 209 | $19.93 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,888 | $19.16 |
| 86701 | <1% | 649 | $19.08 | |
| 87390 | <1% | 643 | $16.50 | |
| 93325 | <1% | 930 | $15.93 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 3,344 | $14.40 |
| 87081 | <1% | 467 | $14.27 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,441 | $14.26 |
| 85018 | <1% | 268 | $12.70 | |
| 86702 | <1% | 648 | $11.81 | |
| 96417 | <1% | 3,054 | $10.18 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 2,623 | $8.46 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,085 | $8.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 3,759 | $7.01 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 227 | $6.65 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 4,266 | $6.55 |
| J7999 | Compounded drug, not otherwise classified | <1% | 257 | $6.38 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 22,916 | $4.34 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 5,874 | $3.77 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 332 | $2.86 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 3,427 | $2.64 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,201 | $2.26 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 587 | $1.24 |
| 88300 | 0% | 423 | $0.00 | |
| 88311 | 0% | 475 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 4,880 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,194 | $0.00 |
| 76377 | 0% | 113 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 52 | $0.00 |
| 88738 | 0% | 436 | $0.00 | |
| 93320 | 0% | 73 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 1,734 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 599 | $0.00 |
| 84157 | 0% | 15 | $0.00 | |
| 99406 | 0% | 72 | $0.00 | |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 108 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 61 | $0.00 |
| 72020 | 0% | 246 | $0.00 | |
| 80329 | 0% | 187 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 345 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 242 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 489 | $0.00 |
| 94760 | 0% | 395 | $0.00 | |
| 95012 | 0% | 12 | $0.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 631 | $0.00 |
| 90656 | 0% | 341 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 80 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 123 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 1,147 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 82 | $0.00 |
| 82150 | 0% | 321 | $0.00 | |
| 12013 | 0% | 52 | $0.00 | |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | 0% | 12 | $0.00 |
| 77001 | 0% | 32 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 105 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 75 | $0.00 |
| 88108 | 0% | 55 | $0.00 | |
| 82950 | 0% | 12 | $0.00 | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 17 | $0.00 |
| 90935 | Hemodialysis procedure with single evaluation by a physician | 0% | 19 | $0.00 |
| 88334 | 0% | 43 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 71 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 15 | $0.00 |
| 83615 | 0% | 100 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 13 | $0.00 |
| A4344 | Indwelling catheter, foley type, two-way, all silicone or polyurethane, each | 0% | 57 | $0.00 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | 0% | 37 | $0.00 |
| 87206 | 0% | 43 | $0.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 15 | $0.00 |
| 86762 | 0% | 13 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 31 | $0.00 |
| 88331 | 0% | 15 | $0.00 | |
| 64484 | 0% | 27 | $0.00 | |
| A9581 | Injection, gadoxetate disodium, 1 ml | 0% | 39 | $0.00 |
| 81003 | 0% | 32 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 331 | $0.00 |
| 88173 | 0% | 1,070 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 714 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 270 | $0.00 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 277 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 757 | $0.00 |
| 89051 | 0% | 310 | $0.00 | |
| 51702 | 0% | 73 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 3,523 | $0.00 |
| 80179 | 0% | 245 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 2,298 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 554 | $0.00 |
| 0042T | 0% | 14 | $0.00 | |
| 76937 | 0% | 1,017 | $0.00 | |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 416 | $0.00 |
| 83540 | 0% | 694 | $0.00 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 153 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,835 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 1,935 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 526 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 561 | $0.00 |
| 91321 | 0% | 68 | $0.00 | |
| 80143 | 0% | 265 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 2,456 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 528 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 203 | $0.00 |
| 94799 | 0% | 119 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 87 | $0.00 |
| 88313 | 0% | 448 | $0.00 | |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | 0% | 478 | $0.00 |
| 96402 | 0% | 113 | $0.00 | |
| 90714 | 0% | 28 | $0.00 | |
| A6251 | Specialty absorptive dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 46 | $0.00 |
| 77338 | 0% | 56 | $0.00 | |
| 87641 | 0% | 40 | $0.00 | |
| 85347 | 0% | 82 | $0.00 | |
| J2598 | Injection, vasopressin, 1 unit | 0% | 25 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 29 | $0.00 |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 27 | $0.00 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 0% | 171 | $0.00 |
| 90662 | 0% | 257 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 27 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 229 | $0.00 |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 0% | 111 | $0.00 |
| 92611 | 0% | 30 | $0.00 | |
| 90734 | 0% | 29 | $0.00 | |
| 77061 | 0% | 28 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 61 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 31 | $0.00 |
| 82272 | 0% | 14 | $0.00 | |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | 0% | 13 | $0.00 |
| J9171 | Injection, docetaxel, 1 mg | 0% | 23 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 124 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 15 | $0.00 |
| 94664 | 0% | 13 | $0.00 | |
| 90746 | 0% | 27 | $0.00 | |
| C1788 | Port, indwelling (implantable) | 0% | 19 | $0.00 |
| 88360 | 0% | 13 | $0.00 | |
| 80164 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPANKS, TIM (EXEC VP/CHIEF FINANCE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| The Queen's Medical Center | Honolulu, HI | $10.29M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.